An integrated microfluidic platform to perform uninterrupted SELEX cycles to screen affinity reagents specific to cardiovascular biomarkers

Sinha, Anirban; Gopinathan, Priya; Chung, Yi-Da; Lin, Hung Jung; Li, Kuang-Hsien; Ma, Hsi-Pin; Huang, Po-Chiun; Shiesh, Shu Chu; Lee, Gwo‐Bin

doi:10.1016/j.bios.2018.09.040

Cited by 74 publications

(39 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…M-SELEX based on microfluidics system capable of handling small volumes of fluid was employed to obtain high affinity aptamers against diverse protein targets recently, including influenza A nucleoprotein (infA NP), ovarian cancer and cardiovascular biomarkers [52,53,54,55]. M-SELEX is a universal and automatable approach for rapid generation of aptamers with high affinity and specificity at the microscale level.…”

Section: Generation Of Aptamersmentioning

confidence: 99%

Recent Advances in Aptamer Discovery and Applications

2019

View full text Add to dashboard Cite

Aptamers are short, single-stranded DNA, RNA, or synthetic XNA molecules that can be developed with high affinity and specificity to interact with any desired targets. They have been widely used in facilitating discoveries in basic research, ensuring food safety and monitoring the environment. Furthermore, aptamers play promising roles as clinical diagnostics and therapeutic agents. This review provides update on the recent advances in this rapidly progressing field of research with particular emphasis on generation of aptamers and their applications in biosensing, biotechnology and medicine. The limitations and future directions of aptamers in target specific delivery and real-time detection are also discussed.

show abstract

Section: Generation Of Aptamersmentioning

confidence: 99%

Recent Advances in Aptamer Discovery and Applications

2019

View full text Add to dashboard Cite

show abstract

“…Researchers have developed different SELEX methods to meet different experimental needs. These methods include capillary electrophoresis-SELEX (CE-SELEX) ( Zhu et al, 2019 ), high-throughput (HT)-SELEX ( Kato et al, 2020 ), microfluidic SELEX ( Sinha et al, 2018 ), and cell SELEX (Harleen and Kaur, 2018 ).…”

Section: Production Of Aptamersmentioning

confidence: 99%

Advances in Screening and Development of Therapeutic Aptamers Against Cancer Cells

Huang

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Cancer has become the leading cause of death in recent years. As great advances in medical treatment, emerging therapies of various cancers have been developed. Current treatments include surgery, radiotherapy, chemotherapy, immunotherapy, and targeted therapy. Aptamers are synthetic ssDNA or RNA. They can bind tightly to target molecules due to their unique tertiary structure. It is easy for aptamers to be screened, synthesized, programmed, and chemically modified. Aptamers are emerging targeted drugs that hold great potentials, called therapeutic aptamers. There are few types of therapeutic aptamers that have already been approved by the US Food and Drug Administration (FDA) for disease treatment. Now more and more therapeutic aptamers are in the stage of preclinical research or clinical trials. This review summarized the screening and development of therapeutic aptamers against different types of cancer cells.

show abstract

“…Another technique termed as systematic evolution of ligands by exponential enrichment (SELEX) has multiple advantages over conventional antibody-based cardiac biomarker detection ( Figure 1C). 139…”

Section: Microfluidicsmentioning

confidence: 99%

“…Another technique termed as systematic evolution of ligands by exponential enrichment (SELEX) has multiple advantages over conventional antibody‐based cardiac biomarker detection (Figure 1C). 139 The SELEX platform consists of an integrated microfluidic device (for sample transport and mixing) and a nucleic acid amplification module. The platform can be used to screen aptamers for protein biomarkers related to CVD, including NT‐proBNP, cTnI, and fibrinogen.…”

Section: Upcoming Technological Advancementsmentioning

confidence: 99%

Liquid biopsy technologies for hematological diseases

Zhang

Khoo

2020

Medicinal Research Reviews

View full text Add to dashboard Cite

Since the discovery of circulating tumor cells in 1869, technological advances in studying circulating biomarkers from patients' blood have made the diagnosis of nonhematologic cancers less invasive. Technological advances in the detection and analysis of biomarkers provide new opportunities for the characterization of other disease types. When compared with traditional biopsies, liquid biopsy markers, such as exfoliated bladder cancer cells, circulating cell‐free DNA (cfDNA), and extracellular vesicles (EV), are considered more convenient than conventional biopsies. Liquid biopsy markers undoubtedly have the potential to influence disease management and treatment dynamics. Our main focuses of this review will be the cell‐based, gene‐based, and protein‐based key liquid biopsy markers (including EV and cfDNA) in disease detection, and discuss the research progress of these biomarkers used in conjunction with liquid biopsy. First, we highlighted the key technologies that have been broadly adopted used in hematological diseases. Second, we introduced the latest technological developments for the specific detection of cardiovascular disease, leukemia, and coronavirus disease. Finally, we concluded with perspectives on these research areas, focusing on the role of microfluidic technology and artificial intelligence in point‐of‐care medical applications. We believe that the noninvasive capabilities of these technologies have great potential in the development of diagnostics and can influence treatment options, thereby advancing precision disease management.

show abstract

An integrated microfluidic platform to perform uninterrupted SELEX cycles to screen affinity reagents specific to cardiovascular biomarkers

Cited by 74 publications

References 37 publications

Recent Advances in Aptamer Discovery and Applications

Recent Advances in Aptamer Discovery and Applications

Advances in Screening and Development of Therapeutic Aptamers Against Cancer Cells

Liquid biopsy technologies for hematological diseases

Contact Info

Product

Resources

About